Levamisole/5-fluorouracil for colon cancer
Executive Summary
Drug combo has been shown to substantially reduce cancer recurrence rates, delay onset of tumor relapse and improve survival rates for patients following surgical treatment, according to study of 408 patients released by NCI Oct. 2. Treatment IND for combo was approved in May. 48% of patients treated with combo were alive five years after therapy compared to 37% who received no post-operative treatment. Study's principal investigator concluded that "the option of therapy with levamisole and 5-FU should be offered to almost all patients who have surgical treatment for high-risk, stage C [Duke's] colon cancer".
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.